MX2021002983A - Agente para tratamiento de trastornos dermatologicos. - Google Patents

Agente para tratamiento de trastornos dermatologicos.

Info

Publication number
MX2021002983A
MX2021002983A MX2021002983A MX2021002983A MX2021002983A MX 2021002983 A MX2021002983 A MX 2021002983A MX 2021002983 A MX2021002983 A MX 2021002983A MX 2021002983 A MX2021002983 A MX 2021002983A MX 2021002983 A MX2021002983 A MX 2021002983A
Authority
MX
Mexico
Prior art keywords
treatment
agent
dermatological disorders
mammal
polypeptide
Prior art date
Application number
MX2021002983A
Other languages
English (en)
Spanish (es)
Inventor
Gino Villetti
Bruno Pietro Imbimbo
Laura Calzà
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2021002983A publication Critical patent/MX2021002983A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2021002983A 2018-09-17 2019-09-17 Agente para tratamiento de trastornos dermatologicos. MX2021002983A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18194930 2018-09-17
EP18203665 2018-10-31
PCT/EP2019/074767 WO2020058217A1 (en) 2018-09-17 2019-09-17 Agent for treatment of dermatological disorders

Publications (1)

Publication Number Publication Date
MX2021002983A true MX2021002983A (es) 2021-05-14

Family

ID=67989007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002983A MX2021002983A (es) 2018-09-17 2019-09-17 Agente para tratamiento de trastornos dermatologicos.

Country Status (11)

Country Link
US (2) US20220064243A1 (https=)
EP (1) EP3852785A1 (https=)
JP (2) JP2022502359A (https=)
KR (1) KR20210061388A (https=)
CN (1) CN113226350B (https=)
AU (1) AU2019343514B2 (https=)
BR (1) BR112021003820A2 (https=)
CA (1) CA3111158A1 (https=)
MA (1) MA53636A (https=)
MX (1) MX2021002983A (https=)
WO (1) WO2020058217A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023536229A (ja) * 2020-07-27 2023-08-24 ヒューマン セル カンパニー Ｎｇｆバリアント、産生、組成物、及び治療的使用
CA3207296A1 (en) * 2021-01-06 2022-07-14 The Penn State Research Foundation Methods and materials for treating hair loss
US12268677B2 (en) 2022-04-27 2025-04-08 The Penn State Research Foundation 4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
EP1482966B1 (en) 2002-03-12 2014-05-14 Bio-Click Technologies Ltd Method and composition for treating skin wounds with epidermal growth factor
ITRM20060367A1 (it) * 2006-07-13 2008-01-14 Lay Line Genomics Spa Muteine del hngf usi terapeutici e composizioni farmaceutiche
WO2010128519A1 (en) 2009-05-04 2010-11-11 Kumar C Jairaj A method for detecting neuropathy and predicting foot ulcer development in human beings with health conditions like diabetes mellitus
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
US20180086805A1 (en) * 2016-05-20 2018-03-29 Chiesi Farmaceutici S.P.A. proNGF mutants and uses thereof for the preparation of NGF mutants

Also Published As

Publication number Publication date
JP2022502359A (ja) 2022-01-11
BR112021003820A2 (pt) 2021-05-25
AU2019343514A1 (en) 2021-04-15
CA3111158A1 (en) 2020-03-26
EP3852785A1 (en) 2021-07-28
JP2025125558A (ja) 2025-08-27
KR20210061388A (ko) 2021-05-27
MA53636A (fr) 2021-12-22
AU2019343514B2 (en) 2025-09-25
CN113226350B (zh) 2024-09-10
WO2020058217A1 (en) 2020-03-26
US20220064243A1 (en) 2022-03-03
CN113226350A (zh) 2021-08-06
US20250277010A1 (en) 2025-09-04

Similar Documents

Publication Publication Date Title
MX2024004439A (es) Agentes terapeuticos para enfermedades neurodegenerativas
ZA202204929B (en) Rimegepant for cgrp related disorders
MX2021002321A (es) Nuevos metodos.
PH12019500845A1 (en) Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
MY199208A (en) Benzemesulfonamide compounds and their use as therapeutic agents
PH12019501074A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
MX2020007049A (es) Peptidos que tienen actividad proteasa para usar en el tratamiento o prevencion de la infeccion por coronavirus.
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
MX2021002983A (es) Agente para tratamiento de trastornos dermatologicos.
MX2020012940A (es) Metodos de uso de moduladores de empalme.
SG10201809099PA (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
MX2020010302A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometilideno)ciclopentano-1- carboxílico y ácido (s)-3-amino-4-(difluorometilenil)ciclopent-1-e no-1-carboxílico en eltratamiento contra trastornos oculares.
JOP20210008A1 (ar) أنواع أبيراز مذابة، وطرق لاستخدامها
MX2016016491A (es) Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas.
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
SA521422315B1 (ar) ببتيدات لعلاج مرض السكرى والاضطربات ذات الصلة والوقاية منها
WO2018045371A3 (en) nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS
EP4066850A3 (en) Peptides and methods of treating dystrophy-related disorders using the same
EP4335508A3 (en) (+)-azasetron for use in the treatment of ear disorders
PH12017501918A1 (en) Multi-peptide composition
MX2021005950A (es) Formulaciones pediatricas acuosas de retinol.
UA137023U (uk) Спосіб лікування меланоми шкіри